Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0779
    -0.0014 (-0.13%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2619
    -0.0003 (-0.03%)
     
  • USD/JPY

    151.2870
    -0.0850 (-0.06%)
     
  • Bitcoin USD

    70,385.68
    +658.59 (+0.94%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,340.06
    +171.99 (+0.43%)
     

Taking the Pulse of These Healthcare Giants - PFE, MRK, JNJ, and ABBV

NEW YORK, NY / ACCESSWIRE / April 8, 2016 / While cheaper medicines continue to pressure firms in the Major Drug Manufacturers space, the segment for many investors still represents a unique investment arena. Today, ValuableInvestment.com takes a closer look at four Healthcare equities: Pfizer Inc. (PFE), Merck & Co. Inc. (MRK), Johnson & Johnson (JNJ), and AbbVie Inc. (ABBV). Get the trade alerts on these names at:

http://valuableinvestment.com/freelaerts

Pfizer Inc.'s stock saw a slight correction of 0.52%, finishing Thursday's trading session at $37.76. A total volume of 61.30 million shares was traded, which was above their three months average volume of 48.71 million shares. In the last month and the previous three months, the stock has advanced 11.58% and 4.68%, respectively. Furthermore, the Company's shares have gained 2.51% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 9.63% and 2.38%, respectively. Moreover, shares of Pfizer have a Relative Strength Index (RSI) of 72.55. Sign up and get the alert on PFE at:

http://valuableinvestment.com/PFE

On Thursday, shares in Merck & Co. Inc. recorded a trading volume of 10.54 million shares and ended the session at $55.42, which was a correction of 0.38% as compared to its previous close. The stock has gained 6.59% in the last one month, 6.65% over the previous three months, and 5.84% since the start of this year. The Company's shares are trading 8.15% above their 50-day moving average and 5.24% above their 200-day moving average. Furthermore, shares of Merck & Co. have an RSI of 73.05. The complimentary alert on MRK can be activated at:

http://valuableinvestment.com/MRK

Johnson & Johnson's shares closed the day at $109.27, slightly down 0.14%. The stock recorded a trading volume of 7.82 million shares. Shares of the Company have gained 2.87% in the last one month, 9.63% in the previous three months, and 7.15% on an YTD basis. The stock is trading 3.70% above its 50-day moving average and 10.12% above its 200-day moving average. Additionally, Johnson & Johnson's shares have an RSI of 65.05. Register for free on ValuableInvestment.com and access the latest strategies on JNJ at:

http://valuableinvestment.com/JNJ

At the closing bell yesterday, shares in AbbVie Inc. ended at $59.30, or 0.99% lower, and with a total volume of 7.83 million shares traded. The stock has advanced 7.19% in the last one month, 4.43% in the previous three months, and 1.15% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 6.27% and 0.28%, respectively. Furthermore, shares of AbbVie have an RSI of 62.68. The complete trade setup on ABBV is available for free at:

http://valuableinvestment.com/ABBV

--

About ValuableInvestment.com:

Valuable Investment was founded in 2006 and has been successfully alerting investors and shareholders of the most profitable ways to earn a living on Wall Street. A decade is a very long time so we must be doing something right. We encourage everyone to come and try our strategy and see how we have been changing the foundation of research for years.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY

ValuableInvestment.com, the Author, the Reviewer, and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither valuableinvestment.com nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To read our disclosures, or for more information, visit http://valuableinvestment.com/

RESTRICTIONS

ValuableInvestment.com is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

E-mail: press@valuableinvestment.com

SOURCE: ValuableInvestment.com

Advertisement